Joining forces creates quick savings. But can vast organizations promote the kind of innovative research they need? Diane Gershon finds out.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gershon, D. Are mega-mergers good medicine for the pharmaceutical industry?. Nature 405, 257–258 (2000). https://doi.org/10.1038/35012205
Issue Date:
DOI: https://doi.org/10.1038/35012205